Pharmacologic treatment of psychiatric and neurodevelopmental disorders in children and adolescents (Part 2).
McDaniel
K D
KD
D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001321:Autistic Disorder / Q000188:drug therapy*; D001569:Benzodiazepines / Q000627:therapeutic use; D002648:Child; D002746:Chlorpromazine / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy*; D008094:Lithium / Q000627:therapeutic use; D008774:Methylphenidate / Q000627:therapeutic use; D011736:Pyridoxine / Q000627:therapeutic use; D012561:Schizophrenia, Childhood / Q000188:drug therapy*; D013881:Thioridazine / Q000627:therapeutic use; D005879:Tourette Syndrome / Q000188:drug therapy*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D008774:Methylphenidate; D008094:Lithium; D006220:Haloperidol; D011736:Pyridoxine; D013881:Thioridazine; D002746:Chlorpromazine